Oncoinvent ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the allocation of 1,531,000 new shares in the Company in a private placement (the "Private Placement") and 119,000 new shares in a retail offering, and a potential subsequent repair offering of up to 200,000 new shares at the same subscription price as in the Private Placement and the retail offering (the "Subsequent Offering"). The Subsequent Offering will, subject to applicable securities law, be directed towards existing shareholders in the Company as of 22 September 2026, as registered in the Company's register of shareholders with Euronext Securities Oslo on 24 September 2026, who (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require a prospectus, filing registration or similar action.

The following key information is provided with respect to the Subsequent Offering:

Date on which the terms and conditions of the Subsequent Offering were announced: 22 September 2026

Last day including right: 22 September 2026

Ex-date: 23 September 2026

Record date: 24 September 2026

Date of approval: 22 September 2026 (subject to final approval by the board of launch of the Subsequent Offering)   

Maximum number of new shares: 200,000

Subscription price: NOK 90 per share

Shall the rights be listed: No

Other information: The Subsequent Offering is subject to, inter alia, completion of the Private Placement, approval by the board of directors, registration of the board authorization to increase the share capital granted by the annual general meeting held on 20 May 2026 (under agenda item 13.4), and the publication of a prospectus. Whether or not the Subsequent Offering will ultimately take place, will depend inter alia on the development of the price of the shares in the Company after completion of the Private Placement, and the Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com